The unique characteristics of COVID-19 coagulopathy

被引:289
作者
Iba, Toshiaki [1 ]
Levy, Jerrold H. [2 ]
Connors, Jean Marie [3 ]
Warkentin, Theodore E. [4 ,5 ]
Thachil, Jecko [6 ]
Levi, Marcel [7 ,8 ]
机构
[1] Juntendo Univ, Grad Sch Med, Dept Emergency & Disaster Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan
[2] Duke Univ, Sch Med, Dept Anesthesiol Crit Care & Surg, Durham, NC USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Hematol Div, Boston, MA 02115 USA
[4] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[5] McMaster Univ, Dept Med, Hamilton, ON, Canada
[6] Manchester Royal Infirm, Dept Haematol, Manchester, Lancs, England
[7] Univ Coll London Hosp NHS Fdn Trust, Dept Med, London, England
[8] Cardiometab Programme NIHR UCLH UCL BRC London, London, England
关键词
COVID-19; Coagulopathy; Disseminated intravascular coagulation; Hemophagocytic syndrome; Antiphospholipid syndrome; Thrombotic microangiopathy; CORONAVIRUS DISEASE 2019; ANTIPHOSPHOLIPID SYNDROME; THERAPEUTIC GUIDELINES; CYTOKINE STORM; MANAGEMENT; DIAGNOSIS; INFECTION; RISK;
D O I
10.1186/s13054-020-03077-0
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Thrombotic complications and coagulopathy frequently occur in COVID-19. However, the characteristics of COVID-19-associated coagulopathy (CAC) are distinct from those seen with bacterial sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC), with CAC usually showing increased D-dimer and fibrinogen levels but initially minimal abnormalities in prothrombin time and platelet count. Venous thromboembolism and arterial thrombosis are more frequent in CAC compared to SIC/DIC. Clinical and laboratory features of CAC overlap somewhat with a hemophagocytic syndrome, antiphospholipid syndrome, and thrombotic microangiopathy. We summarize the key characteristics of representative coagulopathies, discussing similarities and differences so as to define the unique character of CAC.
引用
收藏
页数:8
相关论文
共 56 条
[1]
[Anonymous], 2020, LANCET HAEMATOL, DOI DOI 10.1016/S2352-3026
[2]
[Anonymous], 2019, J Thromb Haemost, DOI DOI 10.1111/JTH.13893
[3]
[Anonymous], J THROMB HAEMOST, DOI DOI 10.1001/JAMA
[4]
[Anonymous], 2016, HAEMOST, DOI DOI 10.1111/JTH.13174
[5]
[Anonymous], 2020, JAMA, DOI DOI 10.1001/JAMA.2020.2648
[6]
[Anonymous], 2020, CRIT CARE MED
[7]
Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome [J].
Azoulay, Elie ;
Knoebl, Paul ;
Garnacho-Montero, Jose ;
Rusinova, Katerina ;
Galstian, Gennadii ;
Eggimann, Philippe ;
Abroug, Fekri ;
Benoit, Dominique ;
von Bergwelt-Baildon, Michael ;
Wendon, Julia ;
Scully, Marie .
CHEST, 2017, 152 (02) :424-434
[8]
Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 [J].
Bowles, Louise ;
Platton, Sean ;
Yartey, Nada ;
Dave, Minal ;
Lee, Kurtis ;
Hart, Daniel P. ;
MacDonald, Vickie ;
Green, Laura ;
Sivapalaratnam, Suthesh ;
Pasi, K. John ;
MacCallum, Peter .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (03) :288-290
[9]
Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? [J].
Campbell, Courtney M. ;
Kahwash, Rami .
CIRCULATION, 2020, 141 (22) :1739-1741
[10]
Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease [J].
Chang, Jae C. .
THROMBOSIS JOURNAL, 2019, 17 (1)